The $4B and $8B numbers were apparently tossed out by DM at the AGM back in October in a sidebar conversation with one of our posters.  How he (DM) came up with that is anybody's guess, but if he is right that would be awesome (although I wouldn't start writing any cheques on that possibility).

As I've said before, I find it hard to believe that a company (and more specifically it's major shareholders) that has been doing research on a product for 20 years would throw in the towel after some positives from a P3 trial and just before they have a chance (Breakthrough Therapy Applications) at some form of commercialization.  Whether the positives are enough to attract a buyer who knows but we'll have a much better idea over the next few months.  If the warrant incentive program doesn't generate any cash then they will surely find some other way to keep things going until some of these matters are resolved.

The highest price an investor would have paid for this stock over the past couple of years is $C4.95.  Warrants aside, for that investor to break even would involve a buyout at about $US3.80.  That's about $800M.  Even at that price many retail investors will generate a pretty good return.  So, if you don't think the company is worth $4B do you think that after all is said and done that it is now worth a minimum of $US800M?  Personally I think the answer is probably yes.  

There are many ways this can play out.  Just have to wait and see what happens.